Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thrombocythemia, Essential × imetelstat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 2 Thrombocythemia, Essential 1 Rhabdomyosarcoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Osteosarcoma 1 Oligodendroglioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Acute 1 Hepatoblastoma 1 Gliosarcoma 1 Glioblastoma 1 Ependymoma 1 Breast Neoplasms 1 Brain Stem Neoplasms 1 Astrocytoma 1

Interventions

fludarabine phosphate 12 Cyclophosphamide 11 Tacrolimus 7 Peripheral Blood Stem Cell Transplantation 7 Mycophenolic Acid 7 Whole-Body Irradiation 6 Busulfan 6 Radiotherapy 5 Methotrexate 5 Cyclosporine 5 ruxolitinib 4 fludarabine 4 Specimen Handling 3 Decitabine 3 Biopsy 3 Antilymphocyte Serum 3 peginterferon alfa-2a 2 givinostat hydrochloride 2 givinostat 2 bomedemstat 2 Stem Cell Transplantation 2 Methylprednisolone 2 Melphalan 2 Imatinib Mesylate 2 Filgrastim 2 Cytarabine 2 Aspirin 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 veliparib 1 tipifarnib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01243073 2016-01-26

ET/PV

Geron Corporation

Phase 2 Completed

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon ⚡